Pentixapharm

Pentixapharm is a clinical-stage radiopharmaceutical company headquartered in Berlin, spun out of Eckert & Ziegler and listed on the Frankfurt Prime Standard since October 2024. Its lead asset is the gallium-68 PET tracer PentixaFor, which distinguishes patients with primary hyperaldosteronism who benefit from adrenal surgery from those better treated with drugs. It completed a €20.4 million capital increase in July 2026, taken up mostly by existing shareholders, to fund the registration-enabling PANDA Phase 3 trial. The tracer received FDA Fast Track designation the same month.